Oncotarget podcast

International Tumor Board Explores Personalized Treatment Options for Glioblastoma With MDM2 and EGFR Amplifications

22/10/2026
0:00
8:42
Reculer de 15 secondes
Avancer de 15 secondes
BUFFALO, NY – October 22, 2026 – A new #case report was #published in Volume 17 of Oncotarget on October 16, 2026, titled “Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR.” The report describes the clinical journey of a 55-year-old man diagnosed with glioblastoma (GBM), an aggressive brain cancer, whose tumor carried amplifications of the MDM2 and EGFR genes alongside other molecular alterations. Through comprehensive genomic profiling and an international molecular tumor board, the case highlights how precision oncology may identify potential treatment strategies when standard therapies offer limited long-term control. The report was led by first and corresponding author Oncotarget Editor-in-Chief Dr. Wafik S. El-Deiry, affiliated with the Worldwide Innovative Network (WIN) Consortium and the Legorreta Cancer Center at Brown University. Equal-contributing author Razelle Kurzrock is affiliated with the WIN Consortium and the Medical College of Wisconsin. Glioblastoma is among the most aggressive primary brain tumors in adults, characterized by rapid growth, extensive infiltration into surrounding tissue and frequent recurrence. Standard treatment generally combines maximal safe surgical resection, radiotherapy and temozolomide chemotherapy. However, median survival remains approximately 15 months, underscoring the need for additional therapeutic approaches. One major challenge is molecular heterogeneity, meaning that tumors can contain genetic alterations that influence growth, treatment response and resistance. Next-generation sequencing (NGS) can help identify these abnormalities and reveal potential targets for individualized treatment. The patient initially experienced dizziness and a generalized seizure in February 2023, followed by impaired speech. Brain imaging revealed a small mass in the left temporal lobe. Following another seizure in June 2023, imaging showed tumor growth, prompting an anterior temporal lobectomy and amygdalohippocampectomy. Histopathological examination confirmed glioblastoma. Full press release - https://www.oncotarget.com/news/pr/international-tumor-board-explores-personalized-treatment-options-for-glioblastoma-with-mdm2-and-egfr-amplifications/ DOI - https://doi.org/10.18632/oncotarget.28920 Correspondence to - Wafik S. El-Deiry - [email protected] Abstract video - https://www.youtube.com/watch?v=s8L4gukgKWU Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28920 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, precision oncology, molecular tumor board, glioblastoma To learn more about the journal, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh [email protected]

D'autres épisodes de "Oncotarget"